Objective: To analyze the clinical effect of budesonide/fomoterol combined with montelukast in the treatment of chronic persistent asthma. Methods: Ninety-four patients with asthma who came to our hospital for treatment from April 2017 to April 2019 were randomly divided into control group and observation group, with 47 patients in each group. The control group was treated with budesonide/formoterol, and the observation group was treated with montelukast on the basis of the control group. The treatment effect of the two groups was observed and compared. Results: The total efficacy rate of the observation group was significantly higher than that of the control group (P0.05); the daytime symptom score and nighttime symptom score of the observation group were significantly higher than those of the control group (P0.05). The pulmonary function indexes of the two groups after treatment were significantly higher than that before treatment, and the improvement of the observation group was more significant (P0.05); the FeNO and EO levels of the observation group after treatment were superior to those of the control group, and the difference was statistically significant (P0.05). Conclusion: Budesonide/formoterol powder inhalation combined with montelukast can effectively improve the lung function, reduce the level of inflammatory factors, and accelerate the regression of symptoms in the treatment of chronic persistent asthma. It is worth clinical application. doi: https://doi.org/10.12669/pjms.36.7.2018 How to cite this:Dai X, Feng T, Zhang X, Li K. Budesonide/Fomoterol in combination with Montelukast in the treatment of Bronchial Asthma. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2018 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
展开▼
机译：目的：分析预烯胺/野鼠与蒙特洛斯特治疗慢性持续性哮喘治疗的临床疗效。方法：从2017年4月到2019年4月到2019年4月，患有哮喘患者的九十四名哮喘患者被随机分为对照组和观察组，每组47名患者。对照组用培养基/福莫特罗治疗，并根据对照组用蒙特洛斯特治疗观察组。观察到两组的治疗效果并进行比较。结果：观察组的总功效率明显高于对照组（P <0.05）;观察组的白天症状评分和夜间症状评分明显高于对照组（P <0.05）。治疗后两组的肺功能指标显着高于治疗前的肺功能指标，观察组的改善更显着（P <0.05）;治疗后观察组的FENO和EO水平优于对照组的那些，差异有统计学意义（P <0.05）。结论：预先用蒙特洛斯特联合肺泡的蛋白质/福莫特罗粉末，可有效改善肺功能，降低炎症因素的水平，加速慢性持续哮喘治疗症状的回归。值得临床应用。 doi：https://doi.org/10.12669/pjms.36.7.2018如何引用这个：戴X，冯t，张x，李克，李克，雌激素与蒙特洛斯特联合治疗支气管哮喘。 Pak J Med Sci。 2020; 36（7）：---------。 DOI：https://doi.org/10.12669/pjms.36.7.2018这是一个开放的访问文章，根据Creative Commons归因许可（http://creativecommons.org/licenses/by/3.0）分发只要正确引用原始工作，允许在任何媒体中不受限制使用，分发和再现。
展开▼
